z-logo
open-access-imgOpen Access
Heterogeneous nuclear ribonucleoprotein K is overexpressed and associated with poor prognosis in gastric cancer
Author(s) -
Ruirui Yang,
Ying Zeng,
Haifan Xu,
Zhuo Chen,
Mengqin Xiang,
Yun Fu,
Yufang Yin,
Jing Zhong,
Min Zeng,
Peihua Wang,
You Qin,
Xi Zeng
Publication year - 2016
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or.2016.4845
Subject(s) - heterogeneous nuclear ribonucleoprotein , cancer , oncogene , ribonucleoprotein , molecular medicine , heterogeneous ribonucleoprotein particle , biomarker , biology , cell cycle , cancer research , pathology , metastasis , medicine , rna , gene , biochemistry
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is one of the major pre-mRNA-binding proteins, that is involved in translational modifications. In our previous studies, we found that hnRNP K is associated with human gastric cancer. The protein levels of hnRNP K were detected in cell lines and tissue microarrays. The correlation between hnRNP K expression and patient survival rate was evaluated by Kaplan-Meier survival analysis. In addition, we also detected hnRNP K expression in preoperative and postoperative serum samples from patients with gastric cancer, and serum samples from healthy volunteers. We found that hnRNP K was overexpressed in the gastric cancer cell lines. The levels of hnRNP K were significantly elevated in the gastric cancer tissues compared with that noted in the tumor-adjacent gastric mucosal and normal gastric mucosal sampes, and hnRNP K expression was found to correlate with tumor stage and lymph node metastasis. However, the level of serum hnRNP K did not differ significantly between gastric cancer patients and healthy volunteers. We also found that patients whose tumors showed elevated expression of hnRNP K had poor survival. The present study suggests that hnRNP K is a promising tissue biomarker for diagnosing gastric cancer and is a prognostic indicator for patients with gastric cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom